At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

TD Cowen downgraded Merck &Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of exclusivity for ...

Repatha, an injectable PCSK9 inhibitor from Amgen, grew sales by 36% last year to $2.2 billion. Even if Merck's orally available option goes on to dominate the PCSK9 space, the company needs ...

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

Merck & Co has said building its cardiovascular ... suggesting it is in the same ballpark for efficacy as its PCSK9 rivals. Lead investigator Christie Ballantyne, of Baylor College of Medicine ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor with an enhanced plasma half-life (between 12 and 15 days).